Botanix Pharmaceuticals Limited (BXPHF)
USD 0.23
(0.0%)
USD 0.23
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 112.46 Million AUD | 352.83% |
| 2023 | 24.83 Million AUD | 76.93% |
| 2022 | 14.03 Million AUD | -36.05% |
| 2021 | 21.95 Million AUD | -13.28% |
| 2020 | 25.31 Million AUD | 386.76% |
| 2019 | 5.19 Million AUD | -70.64% |
| 2018 | 17.71 Million AUD | 199.8% |
| 2017 | 5.9 Million AUD | 59.8% |
| 2016 | 3.69 Million AUD | 179.94% |
| 2015 | 1.32 Million AUD | -48.28% |
| 2014 | 2.55 Million AUD | 31198.96% |
| 2013 | 8158.00 AUD | -54.31% |
| 2012 | 17.85 Thousand AUD | -58.03% |
| 2011 | 42.54 Thousand AUD | -27.38% |
| 2010 | 58.59 Thousand AUD | -97.09% |
| 2009 | 2.01 Million AUD | -14.83% |
| 2008 | 2.36 Million AUD | -32.35% |
| 2007 | 3.5 Million AUD | 39.57% |
| 2006 | 2.5 Million AUD | -31.85% |
| 2005 | 3.67 Million AUD | 51.68% |
| 2004 | 2.42 Million AUD | -17.42% |
| 2003 | 2.93 Million AUD | -34.79% |
| 2002 | 4.5 Million AUD | -23.17% |
| 2001 | 5.86 Million AUD | 11.31% |
| 2000 | 5.26 Million AUD | -67.38% |
| 1999 | 16.14 Million AUD | -46.81% |
| 1998 | 30.36 Million AUD | -39.59% |
| 1997 | 50.26 Million AUD | -11.89% |
| 1996 | 57.04 Million AUD | -16.3% |
| 1995 | 68.15 Million AUD | 40.34% |
| 1994 | 48.56 Million AUD | 27.7% |
| 1993 | 38.03 Million AUD | 46.72% |
| 1992 | 25.92 Million AUD | -5.44% |
| 1991 | 27.41 Million AUD | 7.15% |
| 1990 | 25.58 Million AUD | 6.32% |
| 1989 | 24.06 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 47.68 Million AUD | 0.0% |
| 2024 Q4 | 112.46 Million AUD | 0.0% |
| 2024 FY | 112.46 Million AUD | 352.83% |
| 2024 Q3 | 112.46 Million AUD | 135.87% |
| 2024 Q1 | 47.68 Million AUD | 239.67% |
| 2023 Q1 | 20.78 Million AUD | 48.1% |
| 2023 Q4 | 14.03 Million AUD | -43.48% |
| 2023 Q3 | 24.83 Million AUD | 19.46% |
| 2023 FY | 24.83 Million AUD | 76.93% |
| 2023 Q2 | 20.78 Million AUD | 0.0% |
| 2022 Q1 | 17.29 Million AUD | -21.22% |
| 2022 Q4 | 14.03 Million AUD | 0.0% |
| 2022 Q3 | 14.03 Million AUD | -18.83% |
| 2022 Q2 | 17.29 Million AUD | 0.0% |
| 2022 FY | 14.03 Million AUD | -36.05% |
| 2021 Q3 | 21.95 Million AUD | -17.91% |
| 2021 Q4 | 21.95 Million AUD | 0.0% |
| 2021 Q1 | 26.74 Million AUD | 5.65% |
| 2021 Q2 | 26.74 Million AUD | 0.0% |
| 2021 FY | 21.95 Million AUD | -13.28% |
| 2020 Q3 | 25.31 Million AUD | -28.75% |
| 2020 Q1 | 35.52 Million AUD | 583.16% |
| 2020 FY | 25.31 Million AUD | 386.76% |
| 2020 Q4 | 25.31 Million AUD | 0.0% |
| 2020 Q2 | 35.52 Million AUD | 0.0% |
| 2019 Q4 | 5.19 Million AUD | 0.0% |
| 2019 FY | 5.19 Million AUD | -70.64% |
| 2019 Q1 | 13.88 Million AUD | -21.61% |
| 2019 Q2 | 13.88 Million AUD | 0.0% |
| 2019 Q3 | 5.19 Million AUD | -62.54% |
| 2018 Q2 | 4.13 Million AUD | 0.0% |
| 2018 Q3 | 17.71 Million AUD | 327.92% |
| 2018 Q4 | 17.71 Million AUD | 0.0% |
| 2018 FY | 17.71 Million AUD | 199.8% |
| 2018 Q1 | 4.13 Million AUD | -29.94% |
| 2017 Q4 | 5.9 Million AUD | 0.0% |
| 2017 Q3 | 5.9 Million AUD | 144.63% |
| 2017 FY | 5.9 Million AUD | 59.8% |
| 2017 Q1 | 2.41 Million AUD | -34.68% |
| 2017 Q2 | 2.41 Million AUD | 0.0% |
| 2016 FY | 3.69 Million AUD | 179.94% |
| 2016 Q4 | 3.69 Million AUD | 0.0% |
| 2015 FY | 1.32 Million AUD | -48.28% |
| 2015 Q4 | 1.32 Million AUD | 0.0% |
| 2014 Q4 | 2.55 Million AUD | 0.0% |
| 2014 FY | 2.55 Million AUD | 31198.96% |
| 2013 FY | 8158.00 AUD | -54.31% |
| 2013 Q4 | 8158.00 AUD | 0.0% |
| 2012 Q4 | 17.85 Thousand AUD | 0.0% |
| 2012 FY | 17.85 Thousand AUD | -58.03% |
| 2011 FY | 42.54 Thousand AUD | -27.38% |
| 2011 Q4 | 42.54 Thousand AUD | 0.0% |
| 2010 FY | 58.59 Thousand AUD | -97.09% |
| 2010 Q4 | 58.59 Thousand AUD | 0.0% |
| 2009 Q4 | 2.01 Million AUD | 0.0% |
| 2009 FY | 2.01 Million AUD | -14.83% |
| 2008 FY | 2.36 Million AUD | -32.35% |
| 2008 Q4 | 2.36 Million AUD | 0.0% |
| 2007 Q4 | 3.5 Million AUD | 0.0% |
| 2007 FY | 3.5 Million AUD | 39.57% |
| 2006 Q4 | 2.5 Million AUD | 0.0% |
| 2006 FY | 2.5 Million AUD | -31.85% |
| 2005 FY | 3.67 Million AUD | 51.68% |
| 2005 Q4 | 3.67 Million AUD | 0.0% |
| 2004 Q4 | 2.42 Million AUD | 0.0% |
| 2004 FY | 2.42 Million AUD | -17.42% |
| 2003 FY | 2.93 Million AUD | -34.79% |
| 2003 Q4 | 2.93 Million AUD | 0.0% |
| 2002 Q4 | 4.5 Million AUD | 0.0% |
| 2002 FY | 4.5 Million AUD | -23.17% |
| 2001 Q4 | 5.86 Million AUD | 0.0% |
| 2001 FY | 5.86 Million AUD | 11.31% |
| 2000 Q4 | 5.26 Million AUD | 0.0% |
| 2000 FY | 5.26 Million AUD | -67.38% |
| 1999 Q4 | 16.14 Million AUD | 0.0% |
| 1999 FY | 16.14 Million AUD | -46.81% |
| 1998 FY | 30.36 Million AUD | -39.59% |
| 1997 FY | 50.26 Million AUD | -11.89% |
| 1997 Q4 | 50.26 Million AUD | 0.0% |
| 1996 FY | 57.04 Million AUD | -16.3% |
| 1995 FY | 68.15 Million AUD | 40.34% |
| 1994 FY | 48.56 Million AUD | 27.7% |
| 1993 FY | 38.03 Million AUD | 46.72% |
| 1992 FY | 25.92 Million AUD | -5.44% |
| 1991 FY | 27.41 Million AUD | 7.15% |
| 1990 FY | 25.58 Million AUD | 6.32% |
| 1989 FY | 24.06 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -965.611% |
| BioStem Technologies, Inc. | 14.56 Million USD | -672.406% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 13.629% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -302.464% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -31704.078% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -16258.824% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -5643.298% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -4868498.528% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -14493.59% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -20269.598% |
| Qrons Inc. | 420.00 USD | -26777191.905% |
| Skye Bioscience, Inc. | 11.94 Million USD | -841.882% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -23302.973% |
| Rebus Holdings, Inc. | 5000.00 USD | -2249192.52% |
| CSL Limited | 38.02 Billion USD | 99.704% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -113.401% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -189.507% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -1457.733% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -147193.693% |
| SQZ Biotechnologies Company | 107.18 Million USD | -4.924% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -7753.5% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -155313.012% |
| Mesoblast Limited | 667.9 Million USD | 83.161% |
| Marizyme, Inc. | 22.01 Million USD | -410.853% |
| Genus plc | 1.02 Billion USD | 89.069% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -8179.484% |
| Pharming Group N.V. | 462.85 Million USD | 75.702% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -3294.634% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -22436.24% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -17836.942% |
| ContraFect Corporation | 20.67 Million USD | -443.859% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -28710.046% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -29327.366% |
| IMV Inc. | 31.33 Million USD | -258.924% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -2612.591% |
| MultiCell Technologies, Inc. | 126.22 USD | -89101964.649% |
| ONE Bio Corp. | 70.08 Million USD | -60.468% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -11868.282% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 12.486% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -25950.725% |
| Q BioMed Inc. | 3.51 Million USD | -3099.092% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -219.693% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -42944.212% |
| Biomind Labs Inc. | 73.81 Thousand USD | -152251.869% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 74.801% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -7662.375% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -274.695% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -3995.08% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -4220.252% |
| GB Sciences, Inc. | 103.44 Thousand USD | -108622.401% |
| Alpha Cognition Inc. | 2.45 Million USD | -4486.331% |
| HST Global, Inc. | 1526.00 USD | -7369796.855% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -11283.44% |
| Halberd Corporation | 10.13 Thousand USD | -1110003.899% |
| Enzolytics Inc. | 361.7 Million USD | 68.907% |
| Agentix Corp. | 261.39 Thousand USD | -42925.275% |
| Resverlogix Corp. | 8.11 Million USD | -1285.886% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -5888.914% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 97.524% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -135.765% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -17482.048% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -493577.301% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -1156.707% |
| AVAX Technologies, Inc. | 7.37 Million USD | -1424.498% |
| Zenith Capital Corp. | 7410.00 USD | -1517641.242% |
| Genscript Biotech Corporation | 3.38 Billion USD | 96.679% |
| Ember Therapeutics, Inc. | 184.00 USD | -61121979.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -34847.958% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -42929.884% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -12019.542% |
| Kadimastem Ltd | 2.3 Million USD | -4781.108% |
| Helix BioMedix, Inc. | 3.02 Million USD | -3617.733% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -196881.515% |
| LadRx Corporation | 2.3 Million USD | -4773.067% |
| Cell Source, Inc. | 195.17 Thousand USD | -57523.636% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -31704.078% |
| NovAccess Global Inc. | 62.24 Thousand USD | -180571.871% |
| Affymax, Inc. | 7.44 Million USD | -1411.012% |
| Itoco Inc. | 1.4 Million USD | -7932.774% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -117470.722% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -105998.704% |
| Mobile Lads Corp. | 52.00 USD | -216278026.923% |
| CytoDyn Inc. | 11.13 Million USD | -909.919% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -78561.994% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -628896.79% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -29075.898% |
| SYBLEU INC | 330.46 Thousand USD | -33931.926% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -27369.121% |
| International Stem Cell Corporation | 5.39 Million USD | -1986.542% |
| Bioxytran, Inc. | 137.63 Thousand USD | -81610.448% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -649.673% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -578.356% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -142260.286% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -12906.548% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -1396.137% |
| Neutra Corp. | 2851.00 USD | -3944643.108% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -247.049% |
| PureTech Health plc | 693.97 Million USD | 83.794% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -1293.426% |
| IXICO plc | 15.84 Million USD | -609.829% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -1257.94% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -8.847% |
| CSL Limited | 38.02 Billion USD | 99.704% |
| Cellectis S.A. | 333.99 Million USD | 66.327% |